The loss and damage to Elastin in the skin is recognised as one of the main causes of the symptoms of ageing. Current treatments which aim to maintain or boost Elastin content in the skin struggle to deliver a measurable effect due to the very low levels at which new Elastin is naturally produced in adult skin. In addition, Elastin or Elastin fragments applied topically to the skin are highly unlikely to penetrate the skin surface to meaningful levels.
Elastagen has produced a range of formulations based on recombinant human tropoelastin, a synthetic version of the building block of Elastin which is identical to that present in normal human skin. These formulations will be utilised in a new generation of skin treatments called Elastatherapy™.
Elastagen’s formulations benefit from a unique approach to combine Elastin with Hyaluronic Acid, providing the ability to replace two of the major components which are lost with ageing and skin damage. Preclinical and clinical studies have demonstrated the safety and potential for this approach to augment and repair the skin.
Elastagen is currently conducting clinical trials using Elastatherapy™ with the aim of developing products with utility in both cosmetic and medical dermatology applications.
|Feb ’11||The Science of Elastin|
|Dec ’11||Elastagen Strengthens Board with Appointment of Xavier Yon|
|Oct ’11||Elastagen Featured in Prime Magazine|
|Sep ’11||Elastagen Expands Clinical Program for Elastin Products|
|Dec ’10||Elastagen Initiates Clinical Testing of Elastin Products|
|Dec ’09||Skin Elastin Products A Significant Step Closer|